USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 22, 2024 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| May 22, 2024 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Feb 6, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 6, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 6, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 30, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 15, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 8, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 21, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 035
Our technology is an RNA editing platform that delivers therapies for rare and chronic diseases. We deliver edit-to-cure therapeutics for undruggable target conditions by using RNA-editing to address the root cause of disease progression
First Use Anywhere:
Aug 1, 2022
First Use in Commerce:
Aug 1, 2022
Classification
International Classes
035